FDWM News

News
all
press releases
GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.
Stocktwits
FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.”
Stocktwits
A decision by the FDA on the new submission is expected in the first half of 2026.
Stocktwits

Advertisement|Remove ads.